We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Acorda Asks Fed. Circ. To Undo Nix Of Ampyra Drug Patents

Law360, New York (August 10, 2017, 10:09 PM EDT) -- Acorda on Wednesday kicked off its arguments challenging a Delaware federal judge’s invalidation of the asserted claims of patents covering its blockbuster multiple sclerosis drug Ampyra, contending that the judge erred in concluding that they were obvious.

U.S. District Judge Leonard P. Stark incorrectly used legal tests to conclude that a combination of prior art would have made the asserted claims obvious to an ordinarily skilled artisan, Acorda contended in its defense of the patents covering Ampyra, which generated $493 million last year for Acorda and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.